MOMIPP

Cas No.:	1363421-46-8
Chemical Name:	Momipp
Synonyms:	MOMIPP;(E)-3-(5-Methoxy-2-methyl-1H-indol-3-yl)-1-(pyridin-4-yl)prop-2-en-1-one;NSC781549
SMILES:	O(C([H])([H])[H])C1C([H])=C([H])C2=C(C=1[H])C(/C(/[H])=C(\[H])/C(C1C([H])=C([H])N=C([H])C=1[H])=O)=C(C([H])([H])[H])N2[H]
Formula:	C18H16N2O2
M.Wt:	292.3318
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

In Vivo:	MOMIPP (80 mg/kg; i.p.; once daily; for 15 consecutive days) shows moderately effective in suppressing progression of intracerebral glioblastoma xenografts[2]. Animal Model: Athymic CrTac:NCR-Foxn1 mice (female, 7-8 weeks)[2] Dosage: 80 mg/kg Administration: i.p.; once daily; for 15 consecutive days Result: Suppressed progression of intracerebral glioblastoma xenografts.
In Vitro:	MOMIPP can induce intense macropinocytosis, leading to methuosis in cultured glioblastoma cells at low micromolar concentrations[1]. In U373 and Hs683 cell lines, 3 µM for MOMIPP induces cell vacuolization[1]. MOMIPP (10 μM) causes early disruptions of glucose uptake and glycolytic metabolism. MOMIPP selectively activates the JNK1/2 stress kinase pathway, resulting in phosphorylation of c-Jun, Bcl-2 and Bcl-xL[2]. Western Blot Analysis[2] Cell Line: U251 cells Concentration: 10 μM Incubation Time: 4 h or 24 h Result: Activated the JNK stress kinase pathway.
References:	[1]. Margaux Colin, et al. Dysregulation of Macropinocytosis Processes in Glioblastomas May Be Exploited to Increase Intracellular Anti-Cancer Drug Levels: The Example of Temozolomide. Cancers (Basel). 2019 Mar 22;11(3):411. [2]. Zehui Li, et al. The JNK signaling pathway plays a key role in methuosis (non-apoptotic cell death) induced by MOMIPP in glioblastoma. BMC Cancer. 2019 Jan 16;19(1):77.